Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 17,685 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 17,685 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80. Following the transaction, the chairman directly owned 3,541,122 shares of the company’s stock, valued at $18,697,124.16. The trade was a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.

SOPHiA GENETICS Trading Up 1.7%

SOPHiA GENETICS stock traded up $0.09 during mid-day trading on Wednesday, hitting $5.53. 311,879 shares of the stock were exchanged, compared to its average volume of 188,248. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 12 month low of $2.92 and a 12 month high of $6.30. The firm’s fifty day simple moving average is $5.13 and its two-hundred day simple moving average is $4.97. The stock has a market capitalization of $463.91 million, a price-to-earnings ratio of -10.63 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The recent insider transactions were mostly conducted under pre-arranged Rule 10b5-1 plans and tied to equity-award vesting and tax withholding, which makes them look administrative rather than a sign of deteriorating business prospects. Article Title
• Neutral Sentiment: Multiple top executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others, disclosed share sales on the same date, increasing investor attention on insider activity. Article Title
• Negative Sentiment: Even though the sales were pre-planned, the clustering of insider disposals can still weigh on sentiment near term because it may be seen as added supply and a possible cap on upside. Article Title

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SOPH. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $2,157,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth about $2,009,000. Finally, Sei Investments Co. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.